Cooper, Rachel S.Sutherland, CatherineSmith, Linda M.Cowan, GraemeBarnett, MarkMitchell, DonnaMcLean, ColinImlach, StuartHayes, AlanZahra, SharonManchanayake, ChampaVickers, MarkGraham, GerryMcGowan, NeilTurner, Marc LCampbell, John D MFraser, Alasdair R2025-01-062025-01-062024-07-01Cooper, R S, Sutherland, C, Smith, L M, Cowan, G, Barnett, M, Mitchell, D, McLean, C, Imlach, S, Hayes, A, Zahra, S, Manchanayake, C, Vickers, M, Graham, G, McGowan, N, Turner, M L, Campbell, J D M & Fraser, A R 2024, 'EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation', Frontiers in Immunology, vol. 15. https://doi.org/10.3389/fimmu.2024.14122111664-3224ORCID: /0000-0002-3154-1040/work/175114425https://hdl.handle.net/2164/24827The authors gratefully acknowledge the voluntary donations of peripheral blood and leukapheresis material used in this study. This study was supported by both SNBTS Clinical Apheresis Units and the New Zealand Blood Transfusion Service for the collection of donor leukapheresis material. We also thank the whole SNBTS donor, processing, testing, medical, and nursing teams for their contributions. We would also like to expressly thank Gwen Wilkie and Kirsty Cheal for their work in developing and manufacturing the LCL-derived VST bank and Amy Muir for her contribution in initial peptide-derived VST development during her summer project.165641716engcell therapyEpstein-Barr virusimmunotherapyT cellpotencypeptidelymphoblastoid cell lineT cell receptorR Medicine (General)Supplementary Informationhttps://www.frontiersin.org/articles/10.3389/fimmu.2024.1412211/full#supplementary-materialR1Journal article10.3389/fimmu.2024.141221115